Last update Nov. 5, 2005


Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Anti-arrhythmic withdrawn from the market since the Cardiac Arrhythmia Suppression Trial has reported an excessive mortality ocurrence after myocardial infarction.


We do not have alternatives for Encainide-Hcl.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Encainide-Hcl belongs to this group or family:


Variable Value Unit
Molecular weight 352 daltons
Protein Binding 71 %
Tmax 1.7 hours
36 hours
M/P ratio 1 -
Theoretical Dose 0.06 mg/Kg/d


We are working to add the scientific references of this product. It will be available soon. If you wish to have access to this information, please let us know by leaving your comment in the opinion section below.

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM